HSP90AA1 and Sepsis: Our studies have provided three lines of evidence supporting these findings: (i) serum HSP90α content was significantly higher in patients with sepsis than that of in healthy controls; (ii) compared with surviving septic patients, the elevated serum HSP90α levels were observed in the non-surviving ones; (iii) A higher level of serum HSP90α on admission could identify the 28-day mortality of patients with sepsis.